GIMAP7 Inhibitors
Chemical inhibitors of GIMAP7 operate through various pathways to achieve functional inhibition. Cyclosporin A, for instance, impedes the calcineurin pathway, crucial for T-cell activation, where GIMAP7 plays a role. The inhibition of calcineurin by Cyclosporin A maintains the phosphorylation state of NFAT, preventing its translocation to the nucleus and thus its ability to initiate the transcription of genes involved in T-cell activation. This process is essential for T-cell function, and GIMAP7 is implicated in the survival and maintenance of these cells. Similarly, Rapamycin targets the mTOR pathway, another cornerstone of T-cell proliferation and survival. The compound forms a complex with FKBP12, which then binds to mTOR, suppressing its activity. This suppression disrupts cellular growth signals, thereby reducing the functional capacity of GIMAP7 in the context of T-cell biology.
Delving into kinase inhibition, compounds such as Sphingosine and Staurosporine inhibit protein kinase C (PKC), which is pivotal in cell survival signaling, whereas Wortmannin and LY294002 target the PI3K/AKT pathway, another signaling axis critical for T-cell survival. These inhibitors block the phosphorylation events needed for propagation of survival signals. Consequently, the reduced survival of T-cells indirectly diminishes the role of GIMAP7 in these cells. Furthermore, PD98059 and U0126 are known to interfere with the MAPK/ERK pathway by inhibiting MEK, hindering lymphocyte proliferation and affecting GIMAP7's function in the development and response of T-cells. In a similar vein, SP600125 and SB203580 are inhibitors of the JNK and p38 MAPK pathways, respectively, altering T-cell differentiation and inflammatory responses, which are processes where GIMAP7 is implicated. Finally, Go6983 and Ro-31-8220 are broad-spectrum PKC inhibitors that, by disrupting PKC-mediated signaling, compromise T-cell activation and survival pathways, thus functionally inhibiting the role of GIMAP7 within the immune system.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin after binding to the cytosolic protein cyclophilin. This inhibition prevents dephosphorylation of the nuclear factor of activated T-cells (NFAT), a transcription factor required for T-cell activation. Since GIMAP7 is involved in immune function regulation, specifically in T-lymphocytes, this inhibition downstream reduces the functional activity of GIMAP7 by preventing T-cell activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin forms a complex with FKBP12 and binds to mTOR, inhibiting its kinase activity. mTOR is part of the signaling pathway that regulates cell growth and survival, which are processes fundamental to T-cell function. The inhibition of mTOR by Rapamycin consequently disrupts T-cell proliferation, indirectly affecting the function of GIMAP7 in these cells. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $90.00 $194.00 $510.00 $2448.00 $9384.00 $15300.00 | 2 | |
Sphingosine acts as an inhibitor of protein kinase C, which is involved in the regulation of cell survival and apoptosis. By inhibiting PKC, sphingosine can lead to increased apoptosis, which would decrease the survival of T-cells where GIMAP7 is known to play a role, thus functionally inhibiting GIMAP7. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. By broadly inhibiting these kinases, staurosporine can lead to apoptosis of T-cells, indirectly reducing the functional influence of GIMAP7 in the immune response and T-cell survival. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it disrupts the PI3K/AKT pathway which is involved in regulating T-cell survival. This can indirectly lead to a functional inhibition of GIMAP7 as this pathway is essential for T-cell function and survival. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin, it impedes the PI3K/AKT pathway signaling. This leads to a reduction in T-cell survival and function, thereby indirectly inhibiting GIMAP7's involvement in these processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK) in the MAPK/ERK pathway. Inhibition of MEK by PD98059 disrupts the pathway essential for lymphocyte proliferation, impacting GIMAP7 function in T-cell development and response. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the stress-activated MAPK pathway. Inhibition of JNK affects T-cell differentiation and function, therefore indirectly inhibiting GIMAP7's role in T-cell mediated immune response. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which affects the p38 pathway involved in inflammatory responses and stress signals in cells, including T-lymphocytes. By inhibiting p38 MAPK, SB203580 can indirectly inhibit GIMAP7's function in T-cell survival and immune response. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a pan-PKC inhibitor that by inhibiting PKC can suppress T-cell activation and survival signals, thus indirectly affecting GIMAP7's role in T-cell maintenance and immune system regulation. | ||||||